Price T Rowe Associates Inc Protagonist Therapeutics, Inc Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,309,467 shares of PTGX stock, worth $53.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,309,467

Previous 1,209,542 8.26%

Holding current value

$53.7 Million

Previous $41.9 Million 40.6%

% of portfolio

0.01%

Previous 0.01%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$33.72 - $47.33 $3.37 Million - $4.73 Million	99,925 Added 8.26%	1,309,467 $58.9 Million
Q2 2024 Aug 14, 2024	BUY	$24.66 - $34.8 $9.62 Million - $13.6 Million	390,246 Added 47.63%	1,209,542 $41.9 Million
Q1 2024 May 15, 2024	SELL	$21.79 - $32.15 $96,834 - $142,874	-4,444 Reduced 0.54%	819,296 $23.7 Million
Q4 2023 Feb 14, 2024	SELL	$14.05 - $23.44 $115,954 - $193,450	-8,253 Reduced 0.99%	823,740 $18.9 Million
Q3 2023 Nov 14, 2023	BUY	$16.68 - $23.66 $5,004 - $7,098	300 Added 0.04%	831,993 $13.9 Million
Q2 2023 Aug 14, 2023	BUY	$18.02 - $29.36 $7.5 Million - $12.2 Million	416,419 Added 100.28%	831,693 $23 Million
Q1 2023 May 15, 2023	BUY	$10.78 - $25.38 $4.48 Million - $10.5 Million	415,274 New	415,274 $9.55 Million
Q2 2022 Aug 15, 2022	SELL	$7.06 - $25.52 $2.12 Million - $7.67 Million	-300,468 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$23.34 - $36.08 $1.79 Million - $2.77 Million	-76,664 Reduced 20.33%	300,468 $7.12 Million
Q4 2021 Feb 14, 2022	SELL	$17.63 - $37.1 $2.02 Million - $4.25 Million	-114,509 Reduced 23.29%	377,132 $12.9 Million
Q3 2021 Nov 15, 2021	SELL	$12.95 - $49.69 $6.41 Million - $24.6 Million	-494,613 Reduced 50.15%	491,641 $8.71 Million
Q2 2021 Aug 16, 2021	BUY	$25.57 - $44.88 $1.86 Million - $3.26 Million	72,664 Added 7.95%	986,254 $44.3 Million
Q1 2021 May 17, 2021	BUY	$19.02 - $31.15 $1.3 Million - $2.12 Million	68,195 Added 8.07%	913,590 $23.7 Million
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $15.6 Million - $21.2 Million	845,395 New	845,395 $17 Million

Others Institutions Holding PTGX

# of Institutions

246

Shares Held

56.5M

Call Options Held

76.3K

Put Options Held

114K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.01B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Protagonist Therapeutics, Inc Transaction History